daoib

DAOIB is a small molecule drug that acts as a modulator of the NMDA (N-methyl-D-aspartate) receptor, which is involved in glutamatergic neurotransmission. It has been developed primarily by Chang Gung Memorial Hospital and is being investigated for its potential to enhance NMDA receptor function. The drug's mechanism of action centers on modulating NMDA receptors, which play a critical role in learning, memory, and cognitive processes. DAOIB has reached Phase 2 clinical trials for several indications related to cognitive impairment and neuropsychiatric symptoms, including mental fatigue, post-acute COVID-19 syndrome (long COVID) with brain fog/cognitive impairment, Alzheimer's disease (including mild cognitive impairment), and behavioral and psychological symptoms associated with dementia. Clinical studies suggest that DAOIB may improve cognitive function in patients with early-phase dementia or long-COVID-related brain fog[1][2][5][6].